Journals / Ağrı / 2008 / Cilt: 20 - Sayı: 4

Nöropatik ağrı tedavisinde non-opioid ve opioid ajan kullanımı

Journal
Ağrı
Pages
6–16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There are very few such direct comparisons available.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Treatment of neuropathic pain is difficult despite new treatments and there is no single treatment that Works for all conditions and their underlying mechanisms.
📊
Key Findings & Data:Given the increasing evidence for effective treatments of neuropathic pain, it is important for the clinician to know which drugs are most effective neuropathic pain relieving pain and associated with the fewest adverse effects and there is a need for an evidence-based algorithm to treat neuropathic pain conditions.
💡
Conclusion & Impact:There are very few such direct comparisons available.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Nevralji · Analjezikler · opioid

Abstract

Treatment of neuropathic pain is difficult despite new treatments and there is no single treatment that Works for all conditions and their underlying mechanisms. Given the increasing evidence for effective treatments of neuropathic pain, it is important for the clinician to know which drugs are most effective neuropathic pain relieving pain and associated with the fewest adverse effects and there is a need for an evidence-based algorithm to treat neuropathic pain conditions. Ideally, the evidence for the non-opioids and opioids choices in such an algorithm would be based on direct comparisons of one drug with another, for both efficacy and side effects. There are very few such direct comparisons available.

Özet

Nöropatik ağrı tedavisi yeni tedavilere rağmen hala zordur ve tüm sorunlar ve altta yatan mekanizmaları için işe yarayan tek bir tedavi bulunmamaktadır. Etkin nöropatik ağrı tedavileri için giderek artan kanıtlar göz önüne alınacak olursa, klinisyenin ağrıyı rahatlatmada hangi ilaçların en etkili olduğunu ve ilaçlarla ilişkili en az sayıdaki advers etkileri bilmesi önem kazanmaktadır ve nöropatik ağrı durumlarının tedavi edilmesi için kanıta dayalı bir algoritmaya ihtiyaç duyulmaktadır. İdealde, böyle bir algoritmada non-opioid ve opioid ilaç seçimleri için gereken kanıtlar bir ilacın hem etkinlik hem de yan etkiler açısından diğerleriyle doğrudan bir şekilde karşılaştırılmasına dayalı olmalıdır. Bugün için mevcut olan bu tür doğrudan karşılaştırmalar az sayıdadır.

🔖

Cite This Article

UYAR, M., EYİGÖR, C. (2008). Nöropatik ağrı tedavisinde non-opioid ve opioid ajan kullanımı. Ağrı, Cilt: 20 - Sayı: 4, 6–16. https://ajindex.com/articles/199877

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P. EFSN guidelines on pharmagological treatment of neuropat- hic pain Eur J Neurol 2006; 13: 153-69. Attal N: Chronic neuropathic pain: mechanisms and treatment. The Clinical journal of pain 2000; 16: 118-130.
  2. Baba H, Kohno T, Moore KA, Woolf CJ: Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 2001; 21: 1750–1756.
  3. Backonja MM, Serra J: Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med 2004; 5: 28-47.
  4. Ballantyne JC, Mao J. Opioid therapy for chronic pain. New Engl J Med 2003; 349: 1943-53.
  5. Berger A, Dukes EM, Oster G: Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004; 5: 143-149. Breivik H. Opioids in chronic non-cancer pain, indications and controversies. European Journal of Pain 2005; 9: 127-130.
  6. Buritova J, Besson JM: Peripheral and/or central effects of racemic-, S(+)- and R(-)-flurbiprofen on inflammatory nociceptive processes: A c-Fos protein study in the rat spinal cord. Br J Pharmacol 1998; 125:87–101. Can C. Opioid analjezikler Türkiye Klinkleri Dahili T›p Bilimleri Farmakoloji 2005; 1: 15-23.
  7. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci 2002; 99: 13926-31.
  8. Dani M, Guindon J, Lambert C, Beaulieu P. The local antinoci- ceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. Eur J Pharmacol 2007; 573: 214–215.
  9. Dobecki DA, Schocket SM, Wallace MS. Update on pharmacotherapy guidelines for the treatment for neuropathic pain. Curr Pain Headache Rep 2006; 10: 185-90.
  10. Duhmke RM, CornBlath DD, Hollingshead JR. Tramadol for neuropathic pain Cochrane Database Syst Rev 2004; 2:CD 003726 Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain. Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60: 1524–1534.
  11. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS